First, neither montelukast nor salmeterol provided complete protection against asthma associated with exercise. It may therefore be necessary also to treat some patients with shorter-acting drugs immediately before exercise in addition to longer-acting drugs, such as montelukast or salmeterol. Second, the study did not compare the effect of each drug shortly after it was given (that is, at its “peak effect”). Third, the study evaluated breathing in response to exercise in a laboratory setting rather than in patients' real world settings. Fourth, it is not clear whether the benefit of montelukast would continue beyond 8 weeks. Finally, this study had limited ability to detect unwanted side effects from the drugs, although both drugs appear to be relatively safe. Of note, the company that sells montelukast supported this study.